SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma

被引:17
作者
Hua, Hong-Wei [1 ,3 ]
Jiang, Hao-Sheng [3 ]
Jia, Ling [3 ]
Jia, Yi-Ping [3 ]
Yao, Yu-Lan [3 ]
Chen, Yi-Wen [3 ]
Jiang, Feng [2 ]
Lu, Dong-Qing [1 ]
Zhou, Qing [1 ]
Jiang, Ma-Wei [1 ]
Ding, Gang [3 ]
机构
[1] Shanghai Jiao Tong Univ, Oncol Dept, Xinhua Hosp, Sch Med, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Clin Res & Innovat Unit, Xinhua Hosp, Chongming Branch,Sch Med, Shanghai, Peoples R China
[3] Shanghai Int Med Ctr, Oncol Dept, Shanghai 200120, Peoples R China
关键词
Hepatocellular carcinoma; sorafenib; SPARC; ferroptosis; RESISTANCE; METABOLISM; IRON;
D O I
10.3233/CBM-200101
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Secreted protein acidic and rich in cysteine (SPARC) is implicated in cancer progression, but its role and associated molecular mechanism in the sorafenib sensitivity of hepatocellular carcinoma cells (HCC) remains elusive. METHODS: Human HCC cell lines Hep3B and HepG2 were treated with sorafenib alone or combined with activator or inhibitor of ferroptosis. Cell viability assay, reactive oxygen species (ROS) assay, lactate dehydrogenase (LDH) assay and western blot were used to study the regulatory mechanism of SPARC on HCC cells. RESULTS: Overexpression of SPARC enhanced the cytotoxic effect of sorafenib in Hep3B and HepG2 cells compared with parental cells. Depletion of SPARC decreased the cytotoxic effect of sorafenib in Hep3B and HepG2 cells compared with parental cells. Moreover, overexpression of SPARC significantly induced LDH release, whereas depletion of SPARC suppressed the release of LDH in Hep3B and HepG2 cells. Inhibition of ferroptosis exerted a clear inhibitory role against LDH release, whereas activation of ferroptosis promoted the release of LDH in HCC cells, as accompanied with deregulated expression of ferroptosis-related proteins. Furthermore, overexpression of SPARC induced oxidative stress, whereas depletion of SPARC suppressed the production of ROS. Deferoxamine (DFX)-induced inhibition of ferroptosis suppressed the production of ROS, while activation of ferroptosis promoted the contents of ROS in HCC cells exposed to sorafenib. CONCLUSION: Our findings give a better understanding of ferroptosis and its molecular mechanism in HCC cells that is regulated by SPARC in response to sorafenib.
引用
收藏
页码:425 / 433
页数:9
相关论文
共 26 条
  • [1] Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice
    Angeli, Jose Pedro Friedmann
    Schneider, Manuela
    Proneth, Bettina
    Tyurina, Yulia Y.
    Tyurin, Vladimir A.
    Hammond, Victoria J.
    Herbach, Nadja
    Aichler, Michaela
    Walch, Axel
    Eggenhofer, Elke
    Basavarajappa, Devaraj
    Radmark, Olof
    Kobayashi, Sho
    Seibt, Tobias
    Beck, Heike
    Neff, Frauke
    Esposito, Irene
    Wanke, Ruediger
    Foerster, Heidi
    Yefremova, Olena
    Heinrichmeyer, Marc
    Bornkamm, Georg W.
    Geissler, Edward K.
    Thomas, Stephen B.
    Stockwell, Brent R.
    O'Donnell, Valerie B.
    Kagan, Valerian E.
    Schick, Joel A.
    Conrad, Marcus
    [J]. NATURE CELL BIOLOGY, 2014, 16 (12) : 1180 - U120
  • [2] Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells
    Atorrasagasti, Catalina
    Malvicini, Mariana
    Aquino, Jorge B.
    Alaniz, Laura
    Garcia, Mariana
    Bolontrade, Marcela
    Rizzo, Manglio
    Podhajcer, Osvaldo L.
    Mazzolini, Guillermo
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (11) : 2726 - 2740
  • [3] Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo
    Coriat, Romain
    Nicco, Carole
    Chereau, Christiane
    Mir, Olivier
    Alexandre, Jerome
    Ropert, Stanislas
    Weill, Bernard
    Chaussade, Stanislas
    Goldwasser, Francois
    Batteux, Frederic
    [J]. MOLECULAR CANCER THERAPEUTICS, 2012, 11 (10) : 2284 - 2293
  • [4] Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
    Dixon, Scott J.
    Lemberg, Kathryn M.
    Lamprecht, Michael R.
    Skouta, Rachid
    Zaitsev, Eleina M.
    Gleason, Caroline E.
    Patel, Darpan N.
    Bauer, Andras J.
    Cantley, Alexandra M.
    Yang, Wan Seok
    Morrison, Barclay, III
    Stockwell, Brent R.
    [J]. CELL, 2012, 149 (05) : 1060 - 1072
  • [5] SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
    Feng, Jianguo
    Tang, Liling
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (39) : 6182 - 6190
  • [6] Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC
    Fenouille, Nina
    Puissant, Alexandre
    Dufies, Maeva
    Robert, Guillaume
    Jacquel, Arnaud
    Ohanna, Mickael
    Deckert, Marcel
    Pasquet, Jean-Max
    Mahon, Francois-Xavier
    Cassuto, Jill-Patrice
    Raynaud, Sophie
    Tartare-Deckert, Sophie
    Auberger, Patrick
    [J]. CANCER RESEARCH, 2010, 70 (23) : 9659 - 9670
  • [7] Re-sensitization of 5-FU resistance by SPARC through negative regulation of glucose metabolism in hepatocellular carcinoma
    Hua, Hong-Wei
    Jiang, Feng
    Huang, Qian
    Liao, Zhi-Jun
    Ding, Gang
    [J]. TUMOR BIOLOGY, 2015, 36 (01) : 303 - 313
  • [8] Sorafenib: A Review in Hepatocellular Carcinoma
    Keating, Gillian M.
    [J]. TARGETED ONCOLOGY, 2017, 12 (02) : 243 - 253
  • [9] The Changing Landscape of Hepatocellular Carcinoma Etiology, Genetics, and Therapy
    Knudsen, Erik S.
    Gopal, Purva
    Singal, Amit G.
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2014, 184 (03) : 574 - 583
  • [10] Ferroptosis: Role of lipid peroxidation, iron and ferritinophagy
    Latunde-Dada, Gladys O.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2017, 1861 (08): : 1893 - 1900